1. Home
  2. JCSE vs MYNZ Comparison

JCSE vs MYNZ Comparison

Compare JCSE & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JE Cleantech Holdings Limited

JCSE

JE Cleantech Holdings Limited

HOLD

Current Price

$1.44

Market Cap

12.3M

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$1.18

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JCSE
MYNZ
Founded
1999
2021
Country
Singapore
Germany
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
10.6M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
JCSE
MYNZ
Price
$1.44
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
2.7M
494.5K
Earning Date
10-30-2025
09-26-2025
Dividend Yield
6.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,804,296.00
$659,935.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$0.92
52 Week High
$2.50
$8.20

Technical Indicators

Market Signals
Indicator
JCSE
MYNZ
Relative Strength Index (RSI) 45.17 48.81
Support Level $1.33 $1.08
Resistance Level $2.35 $1.28
Average True Range (ATR) 0.36 0.12
MACD -0.08 -0.00
Stochastic Oscillator 18.66 19.05

Price Performance

Historical Comparison
JCSE
MYNZ

About JCSE JE Cleantech Holdings Limited

JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment ranges from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company derives the majority of its revenue from the Sales of cleaning systems and other equipment. Geographically, the company derives a majority of its revenue from Singapore, followed by Malaysia.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: